The World Health Organization (WHO) released its Global Antibiotic Resistance Surveillance Report 2025, providing the most comprehensive analysis to date of antimicrobial resistance (AMR) worldwide. Based on data from the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS), the report covers over 23 million bacteriologically confirmed infections reported by 104 countries between 2016 and 2023.
Recognizing AI's profound potential to accelerate development, enhance safety monitoring, and bring effective treatments to patients faster, the two agencies have proactively outlined a principles-based framework designed to foster innovation while upholding the non-negotiable pillars of patient safety, product efficacy, and regulatory integrity.
Following a public consultation period (until October 15, 2025), the Algerian Ministry of Health, Ministry of Pharmaceutical Industry, the National Pharmacovigilance and Materiovigilance Centre (CNPM), and the National Agency for Pharmaceutical Products (ANPP) have jointly issued the final Algerian Guide to Good Pharmacovigilance Practices (BPPV) – Version 2.0, December 2025.
This document details the safety signals reviewed and the regulatory actions recommended by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) during its meeting in November 2025.
On January 5, 2026, the landscape of weight management in America shifted with the broad availability of Novo Nordisk's Wegovy® (semaglutide) pill. As the first and only FDA-approved oral GLP-1 receptor agonist for chronic weight management, it represents a monumental shift from injectable therapy, promising to expand access and transform patient experience. However, with...
A new international study protocol, published by the World Health Organization (WHO) in 2025, lays the groundwork for a critical public health initiative: determining how often a rare blood disorder occurs in children across low- and middle-income countries (LMICs). The study focuses on thrombocytopenia—a condition characterized by abnormally low platelet counts that can lead...
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has approved an update to the label for the long-acting contraceptive Depo-Provera (medroxyprogesterone acetate). The change, finalized in December 2025, adds a formal warning about a potential increased risk of developing meningioma, a type of brain tumor. This action follows emerging scientific evidence...
Advancing Medication Safety Through Knowledge and Vigilance
